[Neuroendocrine aspects of Parkinson's disease. Therapeutic/effect of a prolactin inhibitor].
On the basis of a reassessment of the aetiopathogenetic problem and the neuroendocrine implications, the therapeutic effectiveness of a prolactin inhibitor, 2-alpha-Br-ergocryptine (CB 154), in Parkinson's disease is assessed. Five patients were treated for a total of two weeks using doses between 10 and 15 mg/die. CB 154 was found to act as a dopaminergic receptor agonist at nigro-striatal level, considerably improving tremor and rigidity and to a lesser extent bradykinesia and total disability.
D000368:Aged; D001971:Bromocriptine / Q000627:therapeutic use*; D004341:Drug Evaluation; D004873:Ergolines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D011388:Prolactin / Q000037:antagonists & inhibitors*
D004873:Ergolines; D001971:Bromocriptine; D011388:Prolactin
Aspetti neuroendocrinologici del morbo di Parkinson. Interesse all'effetto terapeutico di un inibitore della prolattina